Acute Intermittent Porphyria Market Research Report Information: By Diagnosis (Blood, Urine, DNA, Serum), Treatment (Gonadotropin-Releasing Hormone Analogues, Prophylactic Hematin Infusions), End User (Hospitals & Clinics, Research Centers) - Forecast till 2032

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Acute Intermittent Porphyria Market, by Diagnosis

6.1 Introduction

6.2 Blood Test

6.2.1 Market Estimates & Forecast, 2020-2027

6.3 Urine Test

6.3.1 Market Estimates & Forecast, 2020-2027

6.4 Serum Test

6.4.1 Market Estimates & Forecast, 2020-2027

6.5 DNA test

6.4.1 Market Estimates & Forecast, 2020-2027

7. Global Acute Intermittent Porphyria Market, by Treatment

7.1 Introduction

7.2 Gonadotropin-Releasing Hormone Analogues

7.2.1 Market Estimates & Forecast, 2020-2027

7.3 Prophylactic Hematin Infusions

7.3.1 Market Estimates & Forecast, 2020-2027

8. Global Acute Intermittent Porphyria Market, by End User

8.1 Introduction

8.2 Hospitals & Clinics

8.2.1 Market Estimates & Forecast, 2020-2027

8.3 Research centers

8.3.1 Market Estimates & Forecast, 2020-2027

9. Global Acute Intermittent Porphyria Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 U.S.

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 U.K.

9.3.1.4 Italy

9.3.1.5 Spain

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

11 Company Profiles

11.1 Dahaner Corporation

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 F. Hoffmann-La Roche Ltd

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Bio-Rad Laboratories, Inc

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Siemens AG

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 ARKRAY, Inc.

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Sysmex Corporation

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 ACON Laboratories, Inc

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Others

12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Pharmaceutical Industry

13 Appendix

LIST OF TABLES

Table 1 Acute Intermittent Porphyria Industry Synopsis, 2020-2027

Table 2 Global Acute Intermittent Porphyria Market Estimates and Forecast, 2020-2027, (USD Million)

Table 3 Global Acute Intermittent Porphyria Market by Region, 2020-2027, (USD Million)

Table 4 Global Acute Intermittent Porphyria Market by Diagnosis, 2020-2027, (USD Million)

Table 5 Global Acute Intermittent Porphyria Market by Treatment, 2020-2027, (USD Million)

Table 6 Global Acute Intermittent Porphyria Market by End Users, 2020-2027, (USD Million)

Table 7 North America Acute Intermittent Porphyria Market by Diagnosis, 2020-2027, (USD Million)

Table 8 North America Acute Intermittent Porphyria Market by Treatment, 2020-2027, (USD Million)

Table 9 North America Acute Intermittent Porphyria Market by End Users, 2020-2027, (USD Million)

Table 10 U.S. Acute Intermittent Porphyria Market by Diagnosis, 2020-2027, (USD Million)

Table 11 US Acute Intermittent Porphyria Market by Treatment, 2020-2027, (USD Million)

Table 12 US Acute Intermittent Porphyria Market by End Users, 2020-2027, (USD Million)

Table 13 Canada Acute Intermittent Porphyria Market by Diagnosis, 2020-2027, (USD Million)

Table 14 Canada Acute Intermittent Porphyria Market by Treatment, 2020-2027, (USD Million)

Table 15 Canada Acute Intermittent Porphyria Market by End Users, 2020-2027, (USD Million)

Table 16 South America Acute Intermittent Porphyria Market by Diagnosis, 2020-2027, (USD Million)

Table 17 South America Acute Intermittent Porphyria Market by Treatment, 2020-2027, (USD Million)

Table 18 South America Acute Intermittent Porphyria Market by End Users, 2020-2027, (USD Million)

Table 19 Europe Acute Intermittent Porphyria Market by Diagnosis, 2020-2027, (USD Million)

Table 20 Europe Acute Intermittent Porphyria Market by Treatment, 2020-2027, (USD Million)

Table 21 Europe Acute Intermittent Porphyria Market by End Users, 2020-2027, (USD Million)

Table 22 Western Europe Acute Intermittent Porphyria Market by Diagnosis, 2020-2027, (USD Million)

Table 23 Western Europe Acute Intermittent Porphyria Market by Treatment, 2020-2027, (USD Million)

Table 24 Western Europe Acute Intermittent Porphyria Market by End Users, 2020-2027, (USD Million)

Table 25 Eastern Europe Acute Intermittent Porphyria Market by Diagnosis, 2020-2027, (USD Million)

Table 26 Eastern Europe Acute Intermittent Porphyria Market by Treatment, 2020-2027, (USD Million)

Table 27 Eastern Europe Acute Intermittent Porphyria Market by End Users, 2020-2027, (USD Million)

Table 28 Asia Pacific Acute Intermittent Porphyria Market by Diagnosis, 2020-2027, (USD Million)

Table 29 Asia Pacific Acute Intermittent Porphyria Market by Treatment, 2020-2027, (USD Million)

Table 30 Asia Pacific Acute Intermittent Porphyria Market by End Users, 2020-2027, (USD Million)

Table 31 Middle East & Africa Acute Intermittent Porphyria Market by Diagnosis, 2020-2027, (USD Million)

Table 32 Middle East & Africa Acute Intermittent Porphyria Market by Treatment, 2020-2027, (USD Million)

Table 33 Middle East & Africa Acute Intermittent Porphyria Market by End Users, 2020-2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Acute Intermittent Porphyria Market

Figure 3 Segmentation Market Dynamics for Acute Intermittent Porphyria Market

Figure 4 Global Acute Intermittent Porphyria Market Share, by Diagnosis 2020

Figure 5 Global Acute Intermittent Porphyria Market Share, by Treatment 2020

Figure 6 Global Acute Intermittent Porphyria Market Share, by End Users, 2020

Figure 7 Global Acute Intermittent Porphyria Market Share, by Region, 2020

Figure 8 North America Acute Intermittent Porphyria Market Share, by Country, 2020

Figure 9 Europe Acute Intermittent Porphyria Market Share, by Country, 2020

Figure 10 Asia Pacific Acute Intermittent Porphyria Market Share, by Country, 2020

Figure 11 Middle East & Africa Acute Intermittent Porphyria Market Share, by Country, 2020

Figure 12 Global Acute Intermittent Porphyria Market: Company Share Analysis, 2020 (%)

Figure 13 Dahaner Corporation.: Key Financials

Figure 14 Dahaner Corporation.: Segmental Revenue

Figure 16 Dahaner Corporation.: Geographical Revenue

Figure 17 F. Hoffmann-La Roche Ltd: Key Financials

Figure 18 F. Hoffmann-La Roche Ltd: Segmental Revenue

Figure 19 F. Hoffmann-La Roche Ltd: Geographical Revenue

Figure 20 Bio-Rad Laboratories, Inc: Key Financials

Figure 21 Bio-Rad Laboratories, Inc: Segmental Revenue

Figure 22 Bio-Rad Laboratories, Inc: Geographical Revenue

Figure 23 Siemens AG: Key Financials

Figure 24 Siemens AG: Segmental Revenue

Figure 25 Siemens AG: Geographical Revenue

Figure 26 ARKRAY, Inc..: Key Financials

Figure 27 ARKRAY, Inc.: Segmental Revenue

Figure 28 ARKRAY, Inc.: Geographical Revenue

Figure 29 Sysmex Corporation: Key Financials

Figure 30 Sysmex Corporation: Segmental Revenue

Figure 31 Sysmex Corporation: Geographical Revenue

Figure 32 ACON Laboratories, Inc: Key Financials

Figure 33 ACON Laboratories, Inc: Segmental Revenue

Figure 34 ACON Laboratories, Inc: Geographical Revenue